208 related articles for article (PubMed ID: 36629859)
1. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016-2021.
Reich A; Reed C; Schuster C; Robert C; Treuer T; Lubrano E
J Dermatolog Treat; 2023 Dec; 34(1):2160196. PubMed ID: 36629859
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
[TBL] [Abstract][Full Text] [Related]
5. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium.
Carmona-Rocha E; Puig L
Immunotherapy; 2023 Oct; 15(15):1209-1225. PubMed ID: 37609785
[TBL] [Abstract][Full Text] [Related]
7. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
8. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
[TBL] [Abstract][Full Text] [Related]
9. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting.
Zagni E; Colombo D; Fiocchi M; Perrone V; Sangiorgi D; Andretta M; De Sarro G; Nava E; Degli Esposti L
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):491-497. PubMed ID: 32701033
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
11. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
[TBL] [Abstract][Full Text] [Related]
12. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
13. Disease response and patient-reported outcomes among initiators of ixekizumab.
Shahriari M; Harrison RW; Burge R; Lin CY; Malatestinic WN; Goldblum OM; McLean RR; Crabtree MM; O'Brien J; Grace EL; Murage MJ
J Dermatolog Treat; 2022 May; 33(3):1538-1546. PubMed ID: 33267635
[TBL] [Abstract][Full Text] [Related]
14. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
[TBL] [Abstract][Full Text] [Related]
15. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab.
Egeberg A; Iversen L; Kimball AB; Kelly S; Grace E; Patel H; Xu W; Gallo G; Riedl E; Feldman SR
J Dermatolog Treat; 2022 Aug; 33(5):2503-2509. PubMed ID: 34547967
[TBL] [Abstract][Full Text] [Related]
17. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland.
Koskivirta I; Ruotsalainen J; Kurki S; Lakkakorpi P; Salminen-Mankonen H; Pirilä L; Harvima R; Palomäki A
Scand J Rheumatol; 2023 Sep; 52(5):549-555. PubMed ID: 36644971
[TBL] [Abstract][Full Text] [Related]
18. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Coates LC; Mease P; Kronbergs A; Helt C; Sandoval D; Park SY; Combe B; Nash P; Deodhar A
Clin Rheumatol; 2022 Oct; 41(10):3035-3047. PubMed ID: 35674861
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]